Cardiology Research and Practice / 2021 / Article / Tab 1

Research Article

Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders

Table 1

Patients’ characteristics.

VariablePatients with thrombocytopenia (n = 64)Patients with thrombocytosis (n = 30)Controls (n = 80)Statistical significance
(1)(2)(3)

Platelet count (G/L), mean ± SD (median, min-max)73 ± 34 (79, 11–139)683 ± 230 (567, 452–1136)211 ± 62 (195, 150–371)
(1) vs. (2) vs. (3)
ASA, n (%)64 (100)30 (100)80 (100)NS
Clopidogrel, n (%)15 (23)9 (30)31 (38)NS
Age, years (mean ± SD)68.2 ± 10.654.4 ± 24.661 ± 8.5
(1) vs. (2), (1) vs. (3)
WBC (mean ± SD)6 ± 4.38.3 ± 27 ± 2.8NS
RBC (mean ± SD)3.7 ± 0.84.2 ± 0.64.2 ± 0.7
(1) vs. (3)
Hb (mean ± SD)10.7 ± 2.212.8 ± 2.012.7 ± 2.3
(1) vs. (2) (1) vs. (3)
Arterial hypertension, n  (%)21 (33)12 (40)37 (46)NS
Diabetes mellitus, n (%)11 (17)6 (20)20 (25)NS
Kidney insufficiency, n (%)9 (14)5 (16)10 (12)NS
PCI history, n (%)15 (23)7 (23)49 (61)
(1) vs. (3)
(2) vs. (3)
CABG history, n (%)4 (6)2 (7)8 (10)NS

ASA: acetylsalicylic acid, WBC: white blood cells, RBC: red blood cells, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, Hb: hemoglobin, SD: standard deviation, and NS: no statistical significance ( value above 0.05).